The company had less than $900 million in sales in 2023, the year before it started offering the shots, but is expected by Wall Street to exceed $2.3 billion when it reports 2025 sales on Monday
Factors that may predispose patients to greater heart rate changes include: Higher doses of semaglutide Rapid dose escalation Significant and rapid weight loss Pre-existing cardiovascular conditions Concurrent medications affecting heart rate Dehydration or electrolyte imbalances According to FDA prescribing information, palpitations have been reported in clinical trials, though precise incidence rates vary by product and study population
If the solution appears cloudy, contains floating specks, or shows any color change, the vial may be compromised and should not be used
The cost of fresh syringes is low (around 25 to 35 cents per syringe in bulk), so reuse is never worth it
For institutional investors, the clearest signal of a launch likely to exceed projections is the quality of the IP estate, specifically whether the company has method-of-use patents tied to label language that would survive a Paragraph IV challenge, combined with the breadth of the FDA label and the quality of European HTA preparation that will determine net pricing outside the United States
(2025) "Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study" Thyroid, 35(1) Pasternak, B
